CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Bionano Genomics, Inc. - BNGO CFD

1.1200
6.67%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0300
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Bionano Genomics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.05
Open* 1.08
1-Year Change* -1.68%
Day's Range* 1.08 - 1.15
52 wk Range 1.18-20.20
Average Volume (10 days) 1.91M
Average Volume (3 months) 34.12M
Market Cap 47.39M
P/E Ratio -100.00K
Shares Outstanding 38.84M
Revenue 33.61M
EPS -6.98
Dividend (Yield %) N/A
Beta 2.41
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 1.0500 0.0200 1.94% 1.0300 1.1200 1.0300
Mar 26, 2024 1.0200 -0.0100 -0.97% 1.0300 1.0400 1.0100
Mar 25, 2024 1.0100 -0.0300 -2.88% 1.0400 1.0900 1.0100
Mar 22, 2024 1.0200 -0.0100 -0.97% 1.0300 1.0400 1.0100
Mar 21, 2024 1.0400 -0.0100 -0.95% 1.0500 1.0800 1.0400
Mar 20, 2024 1.0300 0.0100 0.98% 1.0200 1.0400 0.9900
Mar 19, 2024 1.0200 0.0100 0.99% 1.0100 1.0500 1.0000
Mar 18, 2024 1.0100 0.0100 1.00% 1.0000 1.0100 0.9860
Mar 15, 2024 1.0000 -0.0100 -0.99% 1.0100 1.0500 1.0000
Mar 14, 2024 1.0000 -0.0700 -6.54% 1.0700 1.0700 0.9900
Mar 13, 2024 1.0600 0.0100 0.95% 1.0500 1.0900 1.0500
Mar 12, 2024 1.0500 -0.0400 -3.67% 1.0900 1.0900 1.0500
Mar 11, 2024 1.0900 -0.0400 -3.54% 1.1300 1.1700 1.0900
Mar 8, 2024 1.1200 -0.0200 -1.75% 1.1400 1.2400 1.1000
Mar 7, 2024 1.1300 -0.0300 -2.59% 1.1600 1.2100 1.1300
Mar 6, 2024 1.1800 0.0400 3.51% 1.1400 1.2200 1.0500
Mar 5, 2024 1.1800 0.0100 0.85% 1.1700 1.2200 1.1500
Mar 4, 2024 1.2100 -0.0600 -4.72% 1.2700 1.2753 1.1600
Mar 1, 2024 1.2500 -0.0100 -0.79% 1.2600 1.2700 1.2300
Feb 29, 2024 1.2500 -0.0600 -4.58% 1.3100 1.3403 1.2320

Bionano Genomics, Inc. Events

Time (UTC) Country Event
Tuesday, May 7, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Bionano Genomics Inc Earnings Release
Q1 2024 Bionano Genomics Inc Earnings Release

Forecast

-

Previous

-
Thursday, June 13, 2024

Time (UTC)

17:00

Country

US

Event

Bionano Genomics Inc Annual Shareholders Meeting
Bionano Genomics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 27.802 17.981 8.503 10.1295 12.0007
Revenue 27.802 17.981 8.503 10.1295 12.0007
Cost of Revenue, Total 21.857 14.107 5.73 6.76815 8.71133
Gross Profit 5.945 3.874 2.773 3.36136 3.28941
Total Operating Expense 159.5 95.383 47.054 37.3379 32.4158
Selling/General/Admin. Expenses, Total 80.996 55.59 29.468 20.1554 14.2203
Research & Development 49.047 22.485 10.256 9.08089 9.48416
Unusual Expense (Income) 1.8 1.801 1.5 1.3335 0
Operating Income -131.698 -77.402 -38.551 -27.2084 -20.4151
Interest Income (Expense), Net Non-Operating 1.209 -0.691 -2.519 -2.2862 -1.38102
Other, Net -0.223 -0.059 -0.007 -0.29942 3.31523
Net Income Before Taxes -130.712 -78.152 -41.077 -29.794 -18.4809
Net Income After Taxes -132.596 -72.435 -41.106 -29.8151 -18.4964
Net Income Before Extra. Items -132.596 -72.435 -41.106 -29.8151 -18.4964
Net Income -132.596 -72.435 -41.106 -29.8151 -18.4964
Income Available to Common Excl. Extra. Items -132.596 -72.435 -41.106 -29.8151 -18.4964
Income Available to Common Incl. Extra. Items -132.596 -72.435 -41.106 -29.8151 -18.4964
Diluted Net Income -132.596 -72.435 -41.106 -29.8151 -18.4964
Diluted Weighted Average Shares 28.921 27.6782 10.4251 1.49779 1.00551
Diluted EPS Excluding Extraordinary Items -4.58477 -2.61704 -3.94298 -19.906 -18.3951
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -4.54431 -2.57475 -3.84946 -19.3273 -18.3951
Total Extraordinary Items 0
Depreciation / Amortization 5.8 1.4 0.1
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 8.662 7.415 8.215 7.221 6.67
Revenue 8.662 7.415 8.215 7.221 6.67
Cost of Revenue, Total 6.354 5.345 6.41 5.412 5.199
Gross Profit 2.308 2.07 1.805 1.809 1.471
Total Operating Expense 47.9 45.258 45.742 39.37 38.749
Selling/General/Admin. Expenses, Total 26.936 25.976 23.521 21.216 21.783
Research & Development 14.61 13.937 14.011 12.742 11.767
Unusual Expense (Income) 1.8 0 0
Operating Income -39.238 -37.843 -37.527 -32.149 -32.079
Interest Income (Expense), Net Non-Operating 0.615 0.628 0.695 0.363 0.118
Other, Net -0.256 0.117 -0.04 0.005 -0.156
Net Income Before Taxes -38.879 -37.098 -36.872 -31.781 -32.117
Net Income After Taxes -38.912 -37.124 -38.677 -31.809 -32.158
Net Income Before Extra. Items -38.912 -37.124 -38.677 -31.809 -32.158
Net Income -38.912 -37.124 -38.677 -31.809 -32.158
Income Available to Common Excl. Extra. Items -38.912 -37.124 -38.677 -31.809 -32.158
Income Available to Common Incl. Extra. Items -38.912 -37.124 -38.677 -31.809 -32.158
Diluted Net Income -38.912 -37.124 -38.677 -31.809 -32.158
Diluted Weighted Average Shares 31.498 30.2045 29.6953 28.9701 28.5554
Diluted EPS Excluding Extraordinary Items -1.23538 -1.22909 -1.30246 -1.09799 -1.12616
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.23538 -1.22909 -1.26306 -1.09799 -1.12616
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 157.298 272.414 46.789 28.2582 23.0251
Cash and Short Term Investments 113.186 250.612 38.449 17.3114 16.5227
Cash & Equivalents 5.091 24.571 38.449 17.3114 16.5227
Total Receivables, Net 7.496 5.321 2.775 6.33396 4.51433
Accounts Receivable - Trade, Net 7.022 4.934 2.775 6.33396 4.51433
Total Inventory 29.761 12.387 3.315 3.44356 1.06856
Prepaid Expenses 4.443 1.746 1.788 0.71228 0.53537
Other Current Assets, Total 2.412 2.348 0.462 0.45706 0.38413
Total Assets 307.502 377.1 60.45 30.2079 24.8024
Property/Plant/Equipment, Total - Net 28.958 20.935 4.91 1.94963 1.7773
Property/Plant/Equipment, Total - Gross 42.035 30.007 12.366 8.22309 6.93967
Accumulated Depreciation, Total -13.077 -9.072 -7.456 -6.27347 -5.16236
Total Current Liabilities 35.884 21.84 8.945 26.367 4.52286
Accounts Payable 12.534 9.696 2.93 2.69915 1.35174
Accrued Expenses 11.97 10.484 5.037 2.9573 2.90013
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.285 0.299 0 20.0849 0
Other Current Liabilities, Total 11.095 1.361 0.978 0.62562 0.271
Total Liabilities 58.104 39.982 25.368 26.5942 14.6651
Total Long Term Debt 3.619 3.642 16.325 0 9.02937
Long Term Debt 0 16.325 0 9.02937
Other Liabilities, Total 18.601 14.5 0.098 0.22713 1.11283
Total Equity 249.398 337.118 35.082 3.61372 10.1374
Redeemable Preferred Stock 0
Common Stock 0.03 0.029 0.019 0.00343 0.001
Additional Paid-In Capital 599.207 553.747 178.747 106.188 82.8988
Retained Earnings (Accumulated Deficit) -348.715 -216.119 -143.684 -102.577 -72.7624
Total Liabilities & Shareholders’ Equity 307.502 377.1 60.45 30.2079 24.8024
Total Common Shares Outstanding 29.7183 28.9602 18.9953 3.42745 1.00551
Goodwill, Net 77.289 56.16 7.173 0
Intangibles, Net 41.143 26.842 1.475 0
Other Long Term Assets, Total 2.814 0.749 0.103 0
Short Term Investments 108.095 226.041 0
Capital Lease Obligations 3.619 3.642 0
Preferred Stock - Non Redeemable, Net 0 0 0
Other Equity, Total -1.124 -0.539 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 104.537 122.575 142.557 157.298 218.197
Cash and Short Term Investments 63.582 77.062 95.808 113.186 180.19
Cash & Equivalents 34.568 14.856 4.104 5.091 28.166
Total Receivables, Net 8.669 7.613 6.78 7.496 5.829
Accounts Receivable - Trade, Net 8.669 7.613 6.78 7.022 5.829
Total Inventory 26.429 32.453 33.113 29.761 25.046
Prepaid Expenses 5.857 5.447 6.856 4.443 7.132
Total Assets 181.904 271.381 292.151 307.502 323.698
Property/Plant/Equipment, Total - Net 30.991 30.566 29.769 28.958 25.648
Goodwill, Net 0 77.281 77.289 77.289 56.466
Intangibles, Net 35.766 37.559 39.351 41.143 22.585
Other Long Term Assets, Total 10.61 3.4 3.185 2.814 0.802
Total Current Liabilities 40.194 33.499 38.135 35.884 33.5
Accounts Payable 15.369 11.912 15.78 12.534 9.407
Accrued Expenses 12.997 9.416 10.62 11.97 12.757
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 11.552 11.892 11.453 11.095 11.048
Total Liabilities 62.905 56.625 60.664 58.104 41.956
Total Long Term Debt 3.595 3.604 3.612 3.619 3.626
Long Term Debt
Other Liabilities, Total 19.116 19.522 18.917 18.601 4.83
Total Equity 118.999 214.756 231.487 249.398 281.742
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.003 0.003 0.031 0.03 0.03
Additional Paid-In Capital 656.406 639.814 617.96 599.207 593.572
Retained Earnings (Accumulated Deficit) -537.317 -424.751 -385.839 -348.715 -310.038
Total Liabilities & Shareholders’ Equity 181.904 271.381 292.151 307.502 323.698
Total Common Shares Outstanding 35.349 33.24 30.679 29.7183 29.69
Short Term Investments 29.014 62.206 91.704 108.095 152.024
Other Equity, Total -0.093 -0.31 -0.665 -1.124 -1.822
Other Current Assets, Total 2.412
Property/Plant/Equipment, Total - Gross 42.035
Accumulated Depreciation, Total -13.077
Current Port. of LT Debt/Capital Leases 0.276 0.279 0.282 0.285 0.288
Capital Lease Obligations 3.595 3.604 3.612 3.619 3.626
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -132.596 -72.435 -41.106 -29.8151 -18.4964
Cash From Operating Activities -124.816 -71.927 -38.314 -29.5297 -19.9438
Cash From Operating Activities 9.84 3.37 1.479 1.12785 1.32052
Non-Cash Items 24.768 10.567 4.753 4.12957 -0.39911
Cash Interest Paid 0.298 1.91 1.252 1.27718 0.70035
Changes in Working Capital -28.588 -7.652 -3.44 -4.97207 -2.36887
Cash From Investing Activities 82.767 -278.062 -2.45 -0.06106 -0.33172
Capital Expenditures -2.408 -0.822 0 -0.06106 -0.33172
Cash From Financing Activities 23.007 336.111 61.902 30.3794 35.7764
Issuance (Retirement) of Stock, Net 23.471 352.82 68.625 20.4173 19.3935
Issuance (Retirement) of Debt, Net -0.036 -15.005 -4.723 9.82038 16.3829
Net Change in Cash -19.08 -13.878 21.138 0.78864 15.5008
Financing Cash Flow Items -0.428 -1.704 -2 0.14171
Deferred Taxes 1.76 -5.777 0
Other Investing Cash Flow Items, Total 85.175 -277.24 -2.45
Foreign Exchange Effects -0.038
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -37.124 -132.596 -93.919 -62.112 -29.952
Cash From Operating Activities -32.413 -124.816 -90.299 -60.826 -32.494
Cash From Operating Activities 3.241 9.84 7.023 4.592 2.239
Non-Cash Items 4.797 24.768 18.49 12.128 5.779
Cash Interest Paid 0.076 0.298 0.222 0.139 0.07
Changes in Working Capital -3.327 -28.588 -21.893 -15.434 -10.56
Cash From Investing Activities 16.528 82.767 71.157 63.204 31.964
Capital Expenditures -0.36 -2.408 -1.741 -1.451 -0.982
Cash From Financing Activities 14.862 23.007 22.861 0.21 0.007
Financing Cash Flow Items -0.38 -0.428 -0.503 0.075 0
Issuance (Retirement) of Stock, Net 15.252 23.471 23.39 0.152 0.015
Issuance (Retirement) of Debt, Net -0.01 -0.036 -0.026 -0.017 -0.008
Net Change in Cash -0.987 -19.08 3.595 2.588 -0.523
Other Investing Cash Flow Items, Total 16.888 85.175 72.898 64.655 32.946
Deferred Taxes 1.76
Foreign Exchange Effects 0.036 -0.038 -0.124

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Bionano Genomics, Inc. Company profile

Bionano Genomics (BNGO) is a provider of solutions for genome analysis. Additionally, the company offers diagnostic services, software and optical genome mapping solutions for basic, translational and clinical research applications.

Based in San Diego, California, the company has two businesses: Lineagen and BioDiscovery.

Lineagen provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental impairments.

Through BioDiscovery, the company also offers an industry-leading, platform-diagnostic software solution. Integrating next-generation sequencing and microarray data to analyse, visualise, interpret, and report copy number variants, single-nucleotide variants, and the absence of heterozygosity across the genome in a single consolidated view. 

In October 2021, Bionano Genomics bought Biodiscovery, a software company that provides solutions for analysing, interpreting and reporting genomics data.

The acquisition is expected to accelerate the adoption of optical genome mapping (OGM), with the integration of BioDiscovery's NxClinical software solution. Saphyr System is Bionano’s featured product for OGM.

Saphyr is an ultra-sensitive genome analysis platform that can detect structural variations for mosaic samples or heterogeneous cancer samples with a false positive rate of less than 2%.

The company, founded in 2003, sells its products for research use in laboratories associated with academic and governmental research institutions. For North America and Europe, Bionano sells its products through a direct sales force. It also sells its products via third party distributors in China, Japan, South Korea, Singapore, Australia, India and South Africa. 

Bionano became a public company in September 2018. Its shares are traded on the Nasdaq under the ticker symbol BNGO.

Industry: Advanced Medical Equipment & Technology (NEC)

9640 Towne Centre Drive
9640 Towne Centre Drive
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

XRP/USD

0.64 Price
+3.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,218.08 Price
+1.050% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

70,659.20 Price
+2.540% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,236.90 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading